Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The current treatment of scleroderma.

G F Oliver1, R K Winkelmann

  • 1Department of Dermatology, Mayo Clinic, Rochester, Minnesota.

Drugs
|January 1, 1989
PubMed
Summary

Scleroderma treatment varies by disease stage and organ involvement. Newer therapies like heat and plasma exchange show promise for Raynaud

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biphasic sarcomatoid basal cell carcinoma (carcinosarcoma): four cases with immunohistochemistry and review of the literature.

Journal of cutaneous pathology·2004
Same author

Neutrophilic fixed drug eruption.

The Australasian journal of dermatology·2001
Same author

Disseminated cutaneous Mycobacterium avium-intracellulare resembling sarcoidosis.

Journal of the American Academy of Dermatology·1995
Same author

The vascular calcification-cutaneous necrosis syndrome.

Journal of the American Academy of Dermatology·1995
Same author

Successful treatment response of granuloma annulare and carpal tunnel syndrome to chlorambucil.

Mayo Clinic proceedings·1994
Same author

Fatal systemic cytophagic histiocytic panniculitis: a histopathologic and immunohistochemical study of multiple organ sites.

Journal of the American Academy of Dermatology·1994

Area of Science:

  • Rheumatology
  • Internal Medicine
  • Dermatology

Background:

  • Scleroderma management is complex, influenced by disease stage and organ-specific manifestations.
  • Overlapping features with other connective tissue diseases complicate treatment strategies.

Purpose of the Study:

  • To outline current and emerging treatment approaches for scleroderma.
  • To discuss the management of specific scleroderma complications, including Raynaud's phenomenon and renal crisis.

Main Methods:

  • Review of current therapeutic options for scleroderma.
  • Discussion of treatments for Raynaud's phenomenon, renal crisis, and other organ involvements.
  • Evaluation of novel therapeutic strategies such as heat therapy and plasma exchange.

Main Results:

  • Raynaud's phenomenon shows improved response to heat and plasma exchange over traditional vasoactive medications.
  • Low-dose penicillamine is a preferred treatment for stages II and III scleroderma.
  • Angiotensin-converting enzyme inhibitors have significantly reduced mortality associated with scleroderma renal crisis.

Conclusions:

  • Treatment for scleroderma requires a tailored approach based on disease progression and organ involvement.
  • Emerging therapies offer improved outcomes for specific scleroderma complications.
  • Symptomatic management of pulmonary, gastrointestinal, and soft tissue issues remains crucial.

Related Experiment Videos